freeplaytoearngamescrypto| Loss of more than 40 million yuan, sales fee of up to 1.476 billion yuan, Zhendong Pharmaceutical received inquiry letter
Log in to Sina Finance APP to search [Xinpi] to see more evaluation levels.
May 20thFreeplaytoearngamescryptoZhendong Pharmaceutical received an inquiry letter from the Shenzhen Stock Exchange asking it to explain additional issues such as sales expenses, accounts receivable, prepaid accounts, trust financial products, etc.
In 2023, Zhendong Pharmaceutical achieved an operating income of 36.Freeplaytoearngamescrypto.26 billion yuan, with a net profit of-4398.Freeplaytoearngamescrypto.410,000 yuan. Among them, the business income of planting and sales of medicinal materials is 697 million yuan, and the gross profit margin is 10.31%.
The Shenzhen Stock Exchange requires Zhendong Pharmaceutical to explain the name, registered address, registered telephone number, registered email address, registration time, registered capital, number of insured, contributing shareholders and board supervisors of the top 10 customers, whether there is a relationship with the company's director and controlling shareholder, and whether the relevant customer acquisition methods and channels are new customers. Transaction content, recognized amount of cumulative income in the current period and historical reporting period, balance of receivables at the beginning of the period, payback, balance of receivables at the end of the period, age, credit period, provision for bad debts, correspondence, audit procedures adopted and audit evidence obtained Whether there is any overlap between the top 20 suppliers and customers; to provide further information on the planting and sales of medicinal materials.
In 2023, the sales cost of Zhendong Pharmaceutical was 1.476 billion yuan. Of this total, the service fee and market operating fee were 1.053 billion yuan, and the salary of the staff and workers was 216 million yuan, an increase of 54.9584 million yuan over the same period last year.
The Shenzhen Stock Exchange requires Zhendong Pharmaceutical to pay for service fees and market operating fees in 2023, the composition of the main expenditure objects, the name, registered address, registered telephone number, registered email address, registration time, registered capital, number of participants, transaction amount, whether there is a relationship between Zhendong Pharmaceutical and the company's Supervisor Gao and the controlling shareholder, and whether the transaction consideration is fair and the basis for judgment. The relevant payment agreement stipulates the time of payment, the actual time of payment, whether there is a case of advance payment, whether the relevant payment arrangement is commercially reasonable, and whether there is an act of capital occupation by the controlling shareholder through the service provider. The salary policy of staff and workers related to sales expenses, the composition of the total amount, the amount of salary paid per month, the number of in-service salaries per month, the per capita salary and the reasons for fluctuation, whether there is a situation in which the object of expenditure is not on-the-job employees of the company, whether there is a situation in which employees of controlling shareholders are paid in the company.
At the end of 2023, the balance of accounts receivable of Zhendong Pharmaceutical was 858 million yuan, and the balance of accounts receivable for more than three years was 203 million yuan.FreeplaytoearngamescryptoHis book balance of receivables is 78.638 million yuan, and the balance of accounts receivable for more than three years is 34.4666 million yuan.
The Shenzhen Stock Exchange asked Zhendong Pharmaceutical to supplement the names of the top five objects of accounts receivable and other receivables for more than 3 years, registered capital, number of participants, contributing shareholders, and the situation of Supervisor Gao, whether there is a relationship with the company's Supervisor Gao and controlling shareholders, transaction content, transaction amount, credit period, provision for bad debts. The recovery measures taken by the company, whether a lawsuit has been filed, and the subsequent payment arrangements negotiated with the other party.
At the end of 2023, the balance of the prepaid account of Zhendong Pharmaceutical was 99.5971 million yuan, and the equipment engineering, development expenditure and investment funds were 131 million yuan in other non-current assets.
The Shenzhen Stock Exchange requires Zhendong Pharmaceutical to provide supplementary information on the historical cooperation, transaction content, cooperation mode, prepayment reasons, settlement time, and whether the relevant arrangements are in line with business practices. Whether the settlement time is quite different from that of listed companies in the same industry, and whether the counterparty is related to the actual controller of the company and its related parties. Check and explain whether there is a relationship between the name of the prepaid object, the registered capital, the number of participants, the contributing shareholder and the supervisor of your company with a value of more than 10 million in the reporting period, whether there is a relationship between the supervisor and the controlling shareholder of your company, the transaction content, the reason for the advance, the time of prepayment, the time of settlement, whether the corresponding review procedures and information disclosure obligations have been fulfilled, and whether there is a situation of capital occupation.
On April 12, 2024, Zhendong Pharmaceutical disclosed that between 2019 and 2022, the company's controlling shareholders occupy funds through many main bodies, such as Pingshun County Longshuo planting Professional Cooperative, Shanxi Jindu Trading Co., Ltd., Changzhi County Chengcheng Agricultural products Development Co., Ltd. The Shenzhen Stock Exchange requires Zhendong Pharmaceutical to ask annual accountants to combine the shareholders, Dong Jiangao and registered information of several capital occupants disclosed by the company last time, check whether it is related to the top five customers of accounts receivable and other receivables for more than 3 years, prepaid accounts, prepayments in other non-current assets, and sales expenses. The background, content, receipt and payment arrangements and commercial rationality of the relevant transactions should be stated, and whether there are obvious anomalies.
In 2023, a total of 102 million yuan of related transactions occurred between Zhendong Pharmaceutical and Beijing Zhendong Health Technology Co., Ltd., Shanxi Zhendong installation and Decoration Engineering Co., Ltd., Shanxi Zhendong Wuhe Yitang Co., Ltd., and Shanxi Zhendong Construction Engineering Co., Ltd. The Shenzhen Stock Exchange asked Zhendong Pharmaceutical to explain the fairness of the pricing of the above-mentioned related transactions.
At the end of 2023, the final book value of financial products in Zhendong Pharmaceutical's transactional financial assets was 1.448 billion yuan, including 501 million yuan for brokerage wealth management products and 265 million yuan for trust financial products; 29.278 million yuan for bank deposits was limited due to guarantee matters. it is mainly due to the expiration of the ID card of the agent and legal person and the failure to change and freeze the business scope in time. The Shenzhen Stock Exchange asked Zhendong Pharmaceutical to provide supplementary information on the specific conditions of the relevant securities firms, trust financial products, the flow of underlying assets, whether there is a relationship with the controlling shareholder and its related parties, and whether there is a case of limited rights during the reporting period, the review and disclosure of the relevant guarantee matters, and the specific reasons for the freeze.
(source: Beijing News)
Tags:
Prev: thebestplaytoearncryptogames| JPMorgan executives: All new employees will receive artificial intelligence training
Next: futurepinball| Fulin Seiko: A performance briefing meeting will be held on May 20, with investors participating